We recently published a list of Jim Cramer Discussed These 12 Stocks Recently. In this article, we are going to take a look ...
Monitoring and Testing: Product safety tests, including chemical tests, are carried out throughout the ... including both pre- and post-consumer textile waste and PET bottles. This technology also ...
Shares of global pharmaceutical company Merck (NYSE:MRK) fell 11% in the morning session after the company reported mixed fourth-quarter earnings. Its full-year revenue and EPS guidance missed by ...
Merck reported Q4 sales of $15.62 billion, up 7% YoY, exceeding the $15.49 billion estimate. Goldman Sachs raises Merck's price target to $135, citing growth potential. NOW OPEN: 200 Charter ...
For the recently completed fourth quarter, Merck booked an adjusted profit of $1.72 per share on $15.6 billion in revenue. Sales of top-selling cancer treatment Keytruda climbed 19% to $7.84 billion.
Shares of Merck slid Tuesday after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales forecast due partly to a pause in shipments of one of its top-selling products to China.
Merck achieved revenue growth in Q4, but stocks tumbled Tuesday amid news that the company is pausing Gardasil shipments to China. © 2024 Fortune Media IP Limited ...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Merck shares tumbled after the drugmaker said it was halting shipments of a top-selling vaccine to China to ...
Merck (MRK) stock was mangled today after the pharmaceutical and vaccine company released its guidance for 2025. The company expects adjusted earnings per share for the year to range from $8.88 to ...
The pause announcement comes a month after Merck received approval in China for use of the vaccine in males. “We believe China still represents a significant, long-term opportunity for Gardasil ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...